C
Constance M. Yuan
Researcher at National Institutes of Health
Publications - 133
Citations - 10629
Constance M. Yuan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Multiple myeloma. The author has an hindex of 35, co-authored 133 publications receiving 8169 citations.
Papers
More filters
Journal ArticleDOI
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Dickran Kazandjian,Dickran Kazandjian,Elizabeth M. Hill,Alexander Dew,Alexander Dew,Candis Morrison,Joseph Roswarski,Joseph Roswarski,Neha Korde,Neha Korde,Michael Emanuel,Ani Petrosyan,Manisha Bhutani,Katherine R. Calvo,Alina Dulau-Florea,Mary Kwok,Mary Kwok,Min-Jung Lee,Sunmin Lee,Liza Lindenberg,Sham Mailankody,Sham Mailankody,Elisabet E. Manasanch,Elisabet E. Manasanch,Irina Maric,Esther Mena,Nisha Patel,Nishant Tageja,Nishant Tageja,Jane B. Trepel,Baris Turkbey,Hao-Wei Wang,Weixin Wang,Constance M. Yuan,Yong Zhang,Raul C. Braylan,Peter L. Choyke,Maryalice Stetler-Stevenson,Seth M. Steinberg,William D. Figg,Mark Roschewski,Ola Landgren,Ola Landgren +42 more
TL;DR: In this paper, the authors evaluated the use of carfilzomib, lenalidomide, and dexamethasone (KRd) regimens for high-risk smoldering myeloma with a single-arm, single-center, phase 2 nonrandomized controlled trial.
Journal ArticleDOI
Case report: Impact of BITE on CAR‐T cell expansion
Haneen Shalabi,Ashley K. Koegel,Anusha Ponduri,Haiying Qin,Dalia Salem,Dalia Salem,Maryalice Stetler-Stevenson,Constance M. Yuan,Bonnie Yates,Cindy Delbrook,Mignon L. Loh,Terry J. Fry,Terry J. Fry,Nirali N. Shah +13 more
TL;DR: A case of relapsed, refractory B‐ALL that has immunophenotypic variability in the leukemia blasts in response to the sequential targeted immunotherapies received is presented, suggesting a potential strategy for utilization of multiagent immunotherAPies to have synergistic approaches to eradicate disease and prolong remission in patients with relapsed hematologic malignancies.
Journal ArticleDOI
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Dickran Kazandjian,Dickran Kazandjian,Alexander Dew,Alexander Dew,Elizabeth M. Hill,Elizabeth Gil Ramirez,Candis Morrison,Esther Mena,Liza Lindenberg,Constance M. Yuan,Irina Maric,Hao-Wei Wang,Katherine R. Calvo,Alina Dulau-Florea,Joseph Roswarski,Joseph Roswarski,Michael Emanuel,Raul C. Braylan,Baris Turkbey,Peter L. Choyke,Kevin Camphausen,Maryalice Stetler-Stevenson,Seth M. Steinberg,William D. Figg,Jennifer Jones +24 more
TL;DR: In this article, the authors designed a proof-of-principle pilot study to evaluate the synergy between the combination of the anti-PD-L1, avelumab, and concomitant hypofractionated radiotherapy.
Journal ArticleDOI
Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p
Mohammed Farooqui,Janet Valdez,Susan Soto,Maryalice Stetler-Stevenson,Constance M. Yuan,Francine Thomas,Xin Tian,Irina Maric,Adrian Wiestner +8 more
TL;DR: There were no statistically significant differences in response rates by prior tx or del17p status, and stable disease (SD) and progressive disease (PD) each in 2 (2%) pts.
Journal ArticleDOI
Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study
Dickran Kazandjian,Neha Korde,Mark Roschewski,Sham Mailankody,Candis Morrison,Elisabet E. Manasanch,Mary L Kwok,Nishant Tageja,Manisha Bhutani,Adriana Zingone,Rene Costello,Yong Zhang,Marcia Mulquin,Liz Lamping,Ashley Carpenter,Brenda D. Roberson,Irina Maric,Katherine R. Calvo,Raul C. Braylan,Constance M. Yuan,Maryalice Stetler-Stevenson,Diane C. Arthur,Liza Lindenberg,Karen A. Kurdziel,Peter L. Choyke,Seth M. Steinberg,William D. Figg,Wyndham H. Wilson,Ola Landgren +28 more
TL;DR: This phase 2 study of 45 patients demonstrated that deep and durable responses with CRd-R can be achieved in the NDMM setting and expanded on the initial results in assessing minimal residual disease negativity (MRDneg) at complete response (CR) and after 1 and 2 years of LEN maintenance.